Heart failure. Neurohormonal treatment
Two hypothesis on the cause of heart failure (HF) have been postulated, one of hemodynamic character and another one of neurohormonal nature. According to the second one, HF is consequence of the overactivity of endogenous endocrine systems such as the renin-angiotensin aldosterone or the autonomic...
Gespeichert in:
Veröffentlicht in: | Archivos de cardiología de México 2007-10, Vol.77 Suppl 4, p.S4-106-10 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | spa |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 106-10 |
---|---|
container_issue | |
container_start_page | S4 |
container_title | Archivos de cardiología de México |
container_volume | 77 Suppl 4 |
creator | Martínez Reding, Jesús |
description | Two hypothesis on the cause of heart failure (HF) have been postulated, one of hemodynamic character and another one of neurohormonal nature. According to the second one, HF is consequence of the overactivity of endogenous endocrine systems such as the renin-angiotensin aldosterone or the autonomic system. Angiotensin-II blockage is actually the first option in the medical treatment of HF. Since it reduces cardiac and vascular remodelation, synthesis of collagen and improves the endothelial function. Preceding to this option one can find the use of beta adrenergic blochers. Recently it was discovered that atrial myocardium liberates, in response to stretching, several peptides with natriuretic properties, specially one denominated B. Such compound has utility in the treatment of decompensated heart failure exclusively in hospitalized patients. |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70143985</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70143985</sourcerecordid><originalsourceid>FETCH-LOGICAL-p546-3dbd7c1907a297485387a45913e932805f1e48c8cc3b853dbd706ad07c702573</originalsourceid><addsrcrecordid>eNo1T7tOwzAU9QCiJfALKFO3oOvYju0RVUCRKhhgjxznRgTFcfBj4O8Jop3OcN4XZEs5iEprDhtyHeMXQC10La7IhirNlIRmS3YHNCGVgxmnHPC-fMUc_KcPzs9mKlNAkxzO6YZcDmaKeHvCgrw_PX7sD9Xx7fll_3CsFsGbivVdLy3VIE2tJVdiLTFcaMpQs1qBGChyZZW1rFvJPzU0pgdp5TpNsoLs_lOX4L8zxtS6MVqcJjOjz7GVQDnTq7Mgdydh7hz27RJGZ8JPe_7FfgFiNkaX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70143985</pqid></control><display><type>article</type><title>Heart failure. Neurohormonal treatment</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Martínez Reding, Jesús</creator><creatorcontrib>Martínez Reding, Jesús</creatorcontrib><description>Two hypothesis on the cause of heart failure (HF) have been postulated, one of hemodynamic character and another one of neurohormonal nature. According to the second one, HF is consequence of the overactivity of endogenous endocrine systems such as the renin-angiotensin aldosterone or the autonomic system. Angiotensin-II blockage is actually the first option in the medical treatment of HF. Since it reduces cardiac and vascular remodelation, synthesis of collagen and improves the endothelial function. Preceding to this option one can find the use of beta adrenergic blochers. Recently it was discovered that atrial myocardium liberates, in response to stretching, several peptides with natriuretic properties, specially one denominated B. Such compound has utility in the treatment of decompensated heart failure exclusively in hospitalized patients.</description><identifier>ISSN: 1405-9940</identifier><identifier>PMID: 18938706</identifier><language>spa</language><publisher>Mexico</publisher><subject>Adrenergic beta-Antagonists - therapeutic use ; Angiotensin II - antagonists & inhibitors ; Heart Failure - drug therapy ; Humans ; Natriuretic Peptide, Brain - therapeutic use</subject><ispartof>Archivos de cardiología de México, 2007-10, Vol.77 Suppl 4, p.S4-106-10</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18938706$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martínez Reding, Jesús</creatorcontrib><title>Heart failure. Neurohormonal treatment</title><title>Archivos de cardiología de México</title><addtitle>Arch Cardiol Mex</addtitle><description>Two hypothesis on the cause of heart failure (HF) have been postulated, one of hemodynamic character and another one of neurohormonal nature. According to the second one, HF is consequence of the overactivity of endogenous endocrine systems such as the renin-angiotensin aldosterone or the autonomic system. Angiotensin-II blockage is actually the first option in the medical treatment of HF. Since it reduces cardiac and vascular remodelation, synthesis of collagen and improves the endothelial function. Preceding to this option one can find the use of beta adrenergic blochers. Recently it was discovered that atrial myocardium liberates, in response to stretching, several peptides with natriuretic properties, specially one denominated B. Such compound has utility in the treatment of decompensated heart failure exclusively in hospitalized patients.</description><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Angiotensin II - antagonists & inhibitors</subject><subject>Heart Failure - drug therapy</subject><subject>Humans</subject><subject>Natriuretic Peptide, Brain - therapeutic use</subject><issn>1405-9940</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1T7tOwzAU9QCiJfALKFO3oOvYju0RVUCRKhhgjxznRgTFcfBj4O8Jop3OcN4XZEs5iEprDhtyHeMXQC10La7IhirNlIRmS3YHNCGVgxmnHPC-fMUc_KcPzs9mKlNAkxzO6YZcDmaKeHvCgrw_PX7sD9Xx7fll_3CsFsGbivVdLy3VIE2tJVdiLTFcaMpQs1qBGChyZZW1rFvJPzU0pgdp5TpNsoLs_lOX4L8zxtS6MVqcJjOjz7GVQDnTq7Mgdydh7hz27RJGZ8JPe_7FfgFiNkaX</recordid><startdate>200710</startdate><enddate>200710</enddate><creator>Martínez Reding, Jesús</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200710</creationdate><title>Heart failure. Neurohormonal treatment</title><author>Martínez Reding, Jesús</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p546-3dbd7c1907a297485387a45913e932805f1e48c8cc3b853dbd706ad07c702573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2007</creationdate><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Angiotensin II - antagonists & inhibitors</topic><topic>Heart Failure - drug therapy</topic><topic>Humans</topic><topic>Natriuretic Peptide, Brain - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martínez Reding, Jesús</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Archivos de cardiología de México</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martínez Reding, Jesús</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Heart failure. Neurohormonal treatment</atitle><jtitle>Archivos de cardiología de México</jtitle><addtitle>Arch Cardiol Mex</addtitle><date>2007-10</date><risdate>2007</risdate><volume>77 Suppl 4</volume><spage>S4</spage><epage>106-10</epage><pages>S4-106-10</pages><issn>1405-9940</issn><abstract>Two hypothesis on the cause of heart failure (HF) have been postulated, one of hemodynamic character and another one of neurohormonal nature. According to the second one, HF is consequence of the overactivity of endogenous endocrine systems such as the renin-angiotensin aldosterone or the autonomic system. Angiotensin-II blockage is actually the first option in the medical treatment of HF. Since it reduces cardiac and vascular remodelation, synthesis of collagen and improves the endothelial function. Preceding to this option one can find the use of beta adrenergic blochers. Recently it was discovered that atrial myocardium liberates, in response to stretching, several peptides with natriuretic properties, specially one denominated B. Such compound has utility in the treatment of decompensated heart failure exclusively in hospitalized patients.</abstract><cop>Mexico</cop><pmid>18938706</pmid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1405-9940 |
ispartof | Archivos de cardiología de México, 2007-10, Vol.77 Suppl 4, p.S4-106-10 |
issn | 1405-9940 |
language | spa |
recordid | cdi_proquest_miscellaneous_70143985 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Adrenergic beta-Antagonists - therapeutic use Angiotensin II - antagonists & inhibitors Heart Failure - drug therapy Humans Natriuretic Peptide, Brain - therapeutic use |
title | Heart failure. Neurohormonal treatment |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T21%3A14%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Heart%20failure.%20Neurohormonal%20treatment&rft.jtitle=Archivos%20de%20cardiolog%C3%ADa%20de%20M%C3%A9xico&rft.au=Mart%C3%ADnez%20Reding,%20Jes%C3%BAs&rft.date=2007-10&rft.volume=77%20Suppl%204&rft.spage=S4&rft.epage=106-10&rft.pages=S4-106-10&rft.issn=1405-9940&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E70143985%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70143985&rft_id=info:pmid/18938706&rfr_iscdi=true |